|
|
|
|
|
01.04.26 - 22:15
|
Gilead Extends Tender Offer to Acquire Arcellx (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.
The tender offer, which was previously scheduled to expire at one minute after 11:59 p.m., Eastern Time, on April 2, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 24, 2026. The transaction is anticipated to close during the second quarter of 2026, subject to the satisfaction or waiver of...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.03.26 - 16:06
|
Weave Bio Establishes Inaugural Strategic Advisory Board to Shape the Future of AI-Driven Regulatory Science (Business Wire)
|
|
|
Board unites senior regulatory, quality, investment, and AI leaders from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford UniversitySAN FRANCISCO--(BUSINESS WIRE)--$TMV #AIinPharma--Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thought leaders with expertise spanning pharma regulatory strategy and operations, health authority policy and practice, capital markets, and academic research, the SAB will serve as a strategic forum to guide the evolution of the Weave Platform and advance the responsible adoption of AI across the life sciences regulatory ecosystem.
"Regulatory workflows are the backbone of a therapeutic candidate's success, and for too long they have been defined by manual, time-consuming processes that slow the path from discovery to patients," said Brandon Rice, Co-Founder and CEO of Weave Bio. "Our Strategic Advisory Boar...
|
|
|
|
|
24.03.26 - 08:54
|
Rights to antibody drug by China′s Keymed change hands in Gilead acquisition of Ouro (SCMP)
|
|
|
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China's Keymed Biosciences, in a deal worth up to US$2.18 billion.
Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines.
Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion......
|
|
|
24.03.26 - 08:02
|
Gilead mit Doppelschlag (Der Aktionaer)
|
|
|
Zwei milliardenschwere Übernahmen in einem Monat: Die Biotech-Gesellschaft Gilead bleibt äußerst aktiv in Sachen M&A. Nachdem die Amerikaner bereits am 23. Februar die Akquisition des Partners Arcellx bekanntgaben, wurde am gestrigen Montag, also exakt einen Monat später, der geplante Zukauf von Ouro Medicines kommuniziert....
|
|
|
|
|
24.03.26 - 06:54
|
Gilead Sciences To Acquire Ouro Medicines (AFX)
|
|
|
FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD), on Monday, entered into a definitive agreement to acquire privately held Ouro Medicines.The deal includes $1.675 billion in upfront cash, with ......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
